BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Consensus Rating of “Hold” by Analysts

Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) have been assigned a consensus recommendation of “Hold” from the four research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $11.00.

BTAI has been the topic of a number of analyst reports. Wall Street Zen cut shares of BioXcel Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a research note on Friday, July 17th.

BioXcel Therapeutics Price Performance

Shares of NASDAQ BTAI opened at $0.72 on Friday. BioXcel Therapeutics has a one year low of $0.70 and a one year high of $4.29. The firm’s 50 day simple moving average is $0.98 and its two-hundred day simple moving average is $1.20. The stock has a market capitalization of $22.51 million, a P/E ratio of -0.19 and a beta of 0.31.

BioXcel Therapeutics (NASDAQ:BTAI) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). The firm had revenue of $0.18 million for the quarter, compared to analysts’ expectations of $0.48 million. As a group, equities analysts expect that BioXcel Therapeutics will post -2.11 earnings per share for the current fiscal year.

Institutional Trading of BioXcel Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC purchased a new stake in shares of BioXcel Therapeutics during the third quarter valued at approximately $2,632,000. Jane Street Group LLC bought a new stake in BioXcel Therapeutics during the 4th quarter valued at $204,000. Geode Capital Management LLC boosted its position in BioXcel Therapeutics by 64.6% during the 4th quarter. Geode Capital Management LLC now owns 206,168 shares of the company’s stock valued at $330,000 after buying an additional 80,928 shares during the period. Man Group plc bought a new stake in BioXcel Therapeutics in the 4th quarter worth $91,000. Finally, Headlands Technologies LLC purchased a new position in shares of BioXcel Therapeutics in the second quarter valued at about $36,000. Institutional investors own 30.68% of the company’s stock.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.